SCHEMBL1089875

SCHEMBL1089875

CC(Oc1ccccc1)C(=O)N1CCC(N2CCC(Nc3nccc(N4CCCCCC4)n3)C2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR4 P61073 1/20 0.50
▸ HSD17B10 Q99714 2/20 0.44
▸ KDM4E B2RXH2 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ CYP3A4 P08684 2/20 0.41
▸ ACACB O00763 1/20 0.41
▸ HRH4 Q9H3N8 5/20 0.40
▸ TSHR P16473 1/20 0.40
▸ LCK P06239 1/20 0.39
▸ CCNC P24863 1/20 0.39
▸ CDK8 P49336 1/20 0.39
▸ JUN P05412 1/20 0.39
▸ CDK2 P24941 1/20 0.39
▸ MAPK8 P45983 1/20 0.39
▸ MAPK9 P45984 1/20 0.39
▸ SLC6A5 Q9Y345 1/20 0.38
▸ CCNK O75909 1/20 0.38
▸ CDK12 Q9NYV4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1089763 0.96 CXCR4 (0.47) CXCR4HSD17B10KDM4EALDH1A1ALOX15
SCHEMBL1089346 0.96 CXCR4 (0.47) CXCR4HSD17B10KDM4EALDH1A1ALOX15
SCHEMBL1090092 0.92 CXCR4 (0.49) CXCR4HSD17B10KDM4EALDH1A1ALOX15
SCHEMBL1090332 0.89 CXCR4 (0.47) CXCR4HSD17B10KDM4EALDH1A1ALOX15
SCHEMBL1090113 0.88 CXCR4 (0.46) CXCR4HSD17B10KDM4EALDH1A1ALOX15
SCHEMBL1090373 0.87 CXCR4 (0.50) CXCR4CYP3A4ACACBHRH4JUN
SCHEMBL1090810 0.86 CXCR4 (0.54) CXCR4KDM4EALDH1A1CYP3A4ACACB
SCHEMBL1089817 0.84 CXCR4 (0.54) CXCR4KDM4EALDH1A1KMT2ACYP3A4
SCHEMBL1089483 0.84 CXCR4 (0.49) CXCR4CYP3A4ACACBHRH4JUN
SCHEMBL1089894 0.83 CXCR4 (0.49) CXCR4CYP3A4ACACBHRH4JUN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-06-21 — — US disclosed
US-8153625-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-10 — — US disclosed
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-09-02 — — US disclosed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 — — US disclosed
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 — — US disclosed
EP-1571146-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-09-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885HSD17B10 1862/4885KDM4E 2001/4885
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof CXCR4, CXCL12, CXCR3 CXCR4 1/4885HSD17B10 1862/4885KDM4E 2001/4885
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 CXCR4 1/4885HSD17B10 1862/4885KDM4E 2001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback